Mounjaro and Wegovy are changing how obesity gets treated, but the Korean outlet says people who lose weight on them now face a new kind of judgment.
Recap by typeshit. Full story at 헬스조선.
A short Facebook share with no context on who used the peptides, where it happened or what followed.
Benzinga notes a 1.89% after-hours gain for Lilly stock, with Novo Nordisk also tagged. No further detail on what drove the move.
Mikhail Varshavski tells Fox News why protein matters, especially for GLP-1 users. He has a paid partnership with Quest Nutrition.
2:07:50
A live Q&A session covering GLP-1 drugs including Zepbound, Wegovy and Foundayo, with the host taking questions from viewers.
Part of his GLP-1 series, Krittanawong explains how PAD limits blood flow to the legs and causes pain when walking, and asks whether these drugs could help.
Weill Cornell's Dhruv Khullar says vials he had lab tested showed lead, endotoxins, and one held half the advertised dose. Experts warn against 'vibes-based' trust.
Loading…